LifeSci Healthcare Fund

A Share: LYFAX, C Share: LYFCX, I Share: LYFIX

Objective: The Fund’s investment objective is long-term capital appreciation.

The AlphaCentric LifeSci Healthcare Fund Leverages the experience of 20+ PhDs and MDs combined with the hands-on scientific achievements of Portfolio Manager, Mark Charest to invest in Biotech and Healthcare equities to capture long term capital appreciation through fundamental, thesis-driven investments.

The LifeSci Healthcare Fund Difference:

Investment Strategy

  • Designed to outperform broad market exposure by investing in Life Sciences and Healthcare equities leveraging proprietary primary research
  • Emphasizes Science-driven biotechnology and pharmaceutical companies addressing high unmet medical needs

Experienced Team

  • Award winning scientists who have transitioned to successful professional investors..
  • Lead Portfolio Manager Mark G. Charest, Ph.D. has a distinguished scientific background and more than a decade of institutional healthcare investing experience
  • More than a decade of collaboration experience working with LifeSci Partners

Life Sci Platform:

  • Since 2009, LifeSci Partners has been a leading provider of strategic scientific consulting services for innovative healthcare companies
  • Global presence with more than 100 investment and science professionals including 20+ PhD.s and MDs

Fund Management

Fund Commentary

Fund Commentary | Q2 2020

Fund Commentary | Q3 2020

Symmetry Strategy Fund

A Share: SYMAX, C Share: SYMCX, I Share: SYMIX

Objective: The Fund’s investment objective is capital appreciation.

The AlphaCentric Symmetry Strategy Fund utilizes a specifically constructed and repeatable set of investment building blocks designed to capture the available risk premiums during periods of broad economic growth, as well as during periods of economic growth risk.

Investment Strategy

The Fund may invest up to 80% of assets in the Traditional Component Strategy and up to 50% of assets in the Alternative Component Strategy. Under normal conditions, assets will be allocated to each strategy in substantially equal risk adjusted proportions.

Traditional Component Strategy

The Traditional Component Strategy seeks to capture returns that have been historically associated with risk premiums (i.e., the difference between expected return on investment and risk-free rate) for investing in equity and debt securities.

This strategy is expected to benefit from periods of economic growth.

Alternative Component Strategy

The Alternative Component Strategy seeks to capture returns from short term dislocations in currency, interest rate and commodity markets.

The strategy is expected to benefit from periods of economic uncertainty and risk.

Minimum Investment: $2,500, Subsequent Investment: $100

3584-NLD-8/5/2019

Robotics and Automation Fund

A Share: GNXAX, C Share: GNXCX, I Share: GNXIX

Objective: To achieve long‐term growth of capital.

Primary Goals and Key Reasons to Invest:

  • Global Growth Opportunity: We believe growth in robotics for workplace automation has reached a tipping point towards wide-scale adoption Global spending on robotics is rapidly expanding.
  • Thematic Investment Opportunity: The AlphaCentric Robotics and Automation Fund (GNXAX) is the first actively managed mutual fund dedicated to automation and robotics. The Fund is diversified by company industry sector country market capitalization and style and acts as a complement to a diversified equity portfolio.
  • Long-term Growth of Capital: The Fund employs proprietary, bottom up research to identify companies worldwide with innovation technologies such as robotics and automation companies and potential for long‐term out-performance.
  • Disciplined Strategy: The Fund will concentrate its investments (i.e. invest more than 25% of its assets) in the machinery and electrical equipment industries. The Fund may invest without limit in companies located anywhere in the world and under normal conditions at least 40% of the Fund’s assets will be in securities of issuers domiciled in at least countries outside of the United States.

Minimum Investment: $2,500, Subsequent Investment: $100

4999-NLD-8/1/2019

Income Opportunities Fund

A Share: IOFAX, C Share: IOFCX, I Share: IOFIX

Objective: To achieve current income and total return by implementing an alpha-driven, “principles-based” investment process focusing on complex and hard to source asset-backed securities.

Primary Goals and Key Reasons to Invest:

  1. Non-Agency RMBS Focus: The Fund focuses on non-agency residential mortgage-backed securities (RMBS), although the Fund can invest where management finds value. The management team’s clearly-defined, niche focus is the core of the RMBS strategy’s success.
  2. Strong Track Record*: The Sub-Advisor has managed a substantially similar strategy that has consistently met its objective of current income while outperforming its benchmark.
  3. Private Asset Backed Exposure: Unique sourcing to high coupon, well-capitalized proprietary deal flow may lead to additional alpha.

Alpha: A measure of the difference between a fund’s actual returns and its expected performance, given its level of risk as measured by beta.

* See Prospectus for historical performance. Past performance is no guarantee of future results.

Minimum Investment: $2,500, Subsequent Investment: $100

Premium Opportunity Fund

A Share: HMXAX, C Share: HMXCX, I Share: HMXIX

Objective: To achieve capital appreciation with lower overall volatility than the equity market.

Primary Goals and Key Reasons to Invest:

1. Capital Appreciation: Capital Appreciation: The Fund seeks to provide capital appreciation in all market conditions. Since inception, the Fund has weathered volatile financial markets without large drawdowns.
2. Low Correlation: The Fund seeks returns that are uncorrelated to equity markets through a strategy that profits from options time decay, changes in options volatility, options volatility arbitrage, and price and options volatility mean reversion.

Minimum Investment: $2,500, Subsequent Investment: $100

IMPORTANT RISK DISCLOSURES

The Fund is a new mutual fund and has a limited history of operations for investors to evaluate. The fund may be non-diversified and the value and/or volatility of a single issuer could have a greater impact on fund performance. The Fund may be susceptible to an increased risk of loss due to adverse occurrences affecting the Fund more than the market as a whole, because the Funds investments are concentrated. Some securities held by the Fund may be difficult to sell, or illiquid, particularly during times of market turmoil. The Funds’ can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The funds’ can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions by the U.S. Food and Drug Administration. Companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Further, these companies are dependent on patent protection, and the expiration of patents may adversely affect the profitability of the companies. The Fund invests in IPOs at the time of the initial public offering and in post-IPO trading. IPOs are often subject to extreme price volatility and speculative trading. The ETFs in which the fund invests are subject to advisory fees and other expenses and as a result the cost of investing in the fund will be higher than the cost of investing directly in the underlying funds. The Funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. All investments involve risks, including possible loss of principal, there is no assurance that the Fund will achieve its investment objective.

7322-NLD-12/5/2019